CB Therapeutics

CB Therapeutics is a biotechnology company that utilizes a proprietary precision synthetic biology platform to produce complex, high-value natural molecules at scale. By engineering yeast strains to express biosynthetic pathways typically found in plants and fungi, the company transforms renewable feedstocks into rare compounds, including phytocannabinoids, alkaloids, peptides, and terpenes. This platform integrates strain engineering, fermentation, and downstream processing, allowing for repeatable, consistent production that serves as an alternative to traditional agriculture. The company holds a significant intellectual property portfolio, including multiple granted US patents covering its microbial strains, biosynthetic pathways, and analytical methods.

This technology addresses significant supply chain challenges in the pharmaceutical, nutraceutical, and food sectors by offering a reliable, scalable, and sustainable manufacturing process. By enabling the production of compounds that are often difficult to source or synthesize economically, CB Therapeutics supports partners in clinical research, mental health, non-opioid pain management, and healthy aging. The company, which is headquartered in Carlsbad, California, operates a vertically integrated 16,000-square-foot facility that handles every stage of the process, from discovery and strain selection to pilot-scale fermentation and final characterization. Through programs such as TryptageniX and Aevora, the company provides essential ingredients and research data for various therapeutic and wellness applications.